OBJECTIVES To perform comparative pharmacoeconomic analysis of ertapenem in patients with community-acquired complicated intraabdominal infection in comparison with alternative therapy moxifloxacin. METHODS Were reviewed research on the clinical effectiveness and safety of use of ertapenem to prevent postoperative inflammatory complications and lethal outcomes. Assess of  the quality of research and level of evidence obtained in these results was performed. The results of the research PROMISE  formed the basis of pharmacoeconomic model. The effectiveness of therapy in studies was assessed by the frequency of clinical and bacteriological success of treatment with the use of different modes of antibacterial therapy. We calculated the difference in direct medical costs for treatment by ertapenem and moxifloxacin and cost-effectiveness ratio. RESULTS According to a study J.J. De Waele et al., in patients treated with ertapenem, the frequency of clinical effect of treatment was higher than in the group of patients receiving moxifloxacin: 93,4% and 89.5%, respectively.The mortality rate associated with the development of severe sepsis, was also lower for ertapenem : 3,1% and 5.4% respectively. Direct medical  costs accounted in the group of moxifloxacin with the average duration of therapy is 7 days was 1798 USD, in the group of ertapenem with the average duration of treatment 6.8 days - 1981 USD.When using moxifloxacin instead of ertapenem ICER for one additional prevented complication was 4688 USD, and for one surviving patient - 17027 USD. One way sensitivity analyses showed that the results of the model were not sensitive to changing the cost of ertapenem from 75% to 125 %. CONCLUSIONS Pharmacoeconomic analysis showed that the application of ertapenem for the treatment of community-acquired complicated intra-abdominal infections is expensive but more efficient and economically justified strategy.